


GALLIMUNE[®] FLU H5N9

The Inactivated Solution for AI Control. Proven Safe and Effective.

FACT

S h e e t



THE RESPIRATORY SHIELD and THE PERFORMANCE BUILDER are trademarks of Merial. ©1999-2004 Merial Select, Gainesville, Georgia. All rights reserved. GALLIMUNE is a registered trademark of Merial Inc. Corporation Georgia, Athens Georgia ©2002-2004

The Inactivated Solution for AI Control. Proven Safe and Effective.

Characteristics of Gallimune® Flu H5N9

- Proven, inactivated vaccine technology
- Developed from a strain tested at independent laboratories in the USA and Australia
- Complies with OIE guidelines
- Developed in response to the Asian AI outbreaks

Features & Benefits

- Contains H5N9 strain of AI
- The hemagglutinin type that is involved in the current Asian outbreak
- An unusual neuraminidase type that differs from the field strains in the current Asian outbreak
- Allows use of the neuraminidase based DIVA testing methodology
- Uses a 0.2 ml dose in broilers and a 0.3 ml dose in pullets
- Low volume dose for easier, more accurate vaccine administration
- Made with a well characterized low pathogenic AI strain
- As recommended in OIE guidelines
- Safer than unregulated vaccines made from highly pathogenic or uncharacterized AI strains



Serological Response to Gallimune® Flu H5N9

Charts 1 & 2 to the right demonstrate the serological response to Gallimune Flu H5N9.

Materials & Methods

- SPF chickens were used
- Groups 1 & 2 (G1, G2) were vaccinated at 21-28 days old with 0.3ml dose of Gallimune Flu H5N9 intramuscularly
- Group 3 (G3) were unvaccinated controls
- Serum samples were collected at 28 days post vaccination
- Hemagglutination Inhibition tests were performed using homologous H5N9 hemagglutinating antigen

Results

All vaccinated chickens showed a satisfactory serological response with a geometric mean titre (GMT) of 256 (8.0 log₂) or greater (Chart 1). 90% or more of the vaccinated birds had a titre equal to or greater than the GMT (Chart 2).

All of the unvaccinated control birds remained serologically negative.

Conclusions

Gallimune Flu H5N9 was shown to be potent based on serological response.

Chart 1 – Geometric Mean Titre (log₂)





Chart 2 – Percentage Positive at Serial Dilutions



Recommended Vaccination Program

Bird Type	First Vaccination	Second Vaccination	Third Vaccination
BROILERS	Around 7 days	N/A	N/A
PULLETS (in a low challenge area)	Around 7 days	2 – 4 weeks prior to onset of lay	N/A
PULLETS (in a high challenge area)	Around 7 days	6 – 8 weeks prior to onset of lay	2 – 4 weeks prior to onset of lay



AVIAN GLOBAL ENTERPRISE
 Merial Asia Pte. Ltd.
 57A Science Park Drive, The Faraday
 Singapore Science Park 1
 Singapore 118238
 Tel: (65).6778.5977 Fax: (65).6776.6903